http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Aug 2026 06:05:52 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Lucid+Capital+Markets+Starts+Eloxx+Pharma++%28ELOX%29+at+Buy/26952343.html (Updated - August 20, 2026 6:05 AM EDT) <p>Lucid Capital Markets analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Buy rating and a price target of $38.00.</p><p>The analyst comments "We initiate coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and a $38 price target, reflecting an attractive risk/reward profile ahead of the mid-2027 EXACT Phase 2b readout in nonsense-mutation Alport syndrome (NMAS). The lead asset, exaluren, is designed to restore full-length protein production in diseases caused by nonsense mutations. Preliminary Phase 2a data in three NMAS patients showed a mean 72% increase in collagen IV α3/α4 http://www.streetinsider.com/New+Coverage/Lucid+Capital+Markets+Starts+Eloxx+Pharma++%28ELOX%29+at+Buy/26952343.html Thu, 20 Aug 2026 06:05:52 -0400 ELOX http://www.streetinsider.com/Analyst+Comments/Lucid+Capital+Markets+Starts+Eloxx+Pharma++%28ELOX%29+at+Buy/26952343.html (Updated - August 20, 2026 6:05 AM EDT) <p>Lucid Capital Markets analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Buy rating and a price target of $38.00.</p><p>The analyst comments "We initiate coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and a $38 price target, reflecting an attractive risk/reward profile ahead of the mid-2027 EXACT Phase 2b readout in nonsense-mutation Alport syndrome (NMAS). The lead asset, exaluren, is designed to restore full-length protein production in diseases caused by nonsense mutations. Preliminary Phase 2a data in three NMAS patients showed a mean 72% increase in collagen IV α3/α4 http://www.streetinsider.com/Analyst+Comments/Lucid+Capital+Markets+Starts+Eloxx+Pharma++%28ELOX%29+at+Buy/26952343.html Thu, 20 Aug 2026 06:05:52 -0400 ELOX http://www.streetinsider.com/Hot+Comments/Lucid+Capital+Markets+Starts+Eloxx+Pharma++%28ELOX%29+at+Buy/26952343.html (Updated - August 20, 2026 6:05 AM EDT) <p>Lucid Capital Markets analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Buy rating and a price target of $38.00.</p><p>The analyst comments "We initiate coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and a $38 price target, reflecting an attractive risk/reward profile ahead of the mid-2027 EXACT Phase 2b readout in nonsense-mutation Alport syndrome (NMAS). The lead asset, exaluren, is designed to restore full-length protein production in diseases caused by nonsense mutations. Preliminary Phase 2a data in three NMAS patients showed a mean 72% increase in collagen IV α3/α4 http://www.streetinsider.com/Hot+Comments/Lucid+Capital+Markets+Starts+Eloxx+Pharma++%28ELOX%29+at+Buy/26952343.html Thu, 20 Aug 2026 06:05:52 -0400 ELOX http://www.streetinsider.com/Hot+New+Coverage/Lucid+Capital+Markets+Starts+Eloxx+Pharma++%28ELOX%29+at+Buy/26952343.html (Updated - August 20, 2026 6:05 AM EDT) <p>Lucid Capital Markets analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Buy rating and a price target of $38.00.</p><p>The analyst comments "We initiate coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and a $38 price target, reflecting an attractive risk/reward profile ahead of the mid-2027 EXACT Phase 2b readout in nonsense-mutation Alport syndrome (NMAS). The lead asset, exaluren, is designed to restore full-length protein production in diseases caused by nonsense mutations. Preliminary Phase 2a data in three NMAS patients showed a mean 72% increase in collagen IV α3/α4 http://www.streetinsider.com/Hot+New+Coverage/Lucid+Capital+Markets+Starts+Eloxx+Pharma++%28ELOX%29+at+Buy/26952343.html Thu, 20 Aug 2026 06:05:52 -0400 ELOX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Eloxx+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./26932275.html si-local-file:///var/storage/secattach/20260814/26932275.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Eloxx+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./26932275.html Fri, 14 Aug 2026 16:54:00 -0400 ELOX O.02268824 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Eloxx+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./26932275.html si-local-file:///var/storage/secattach/20260814/26932275.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Eloxx+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./26932275.html Fri, 14 Aug 2026 16:54:00 -0400 ELOX O.02268824 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Eloxx+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932028.html si-local-file:///var/storage/secattach/20260814/26932028.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Eloxx+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932028.html Fri, 14 Aug 2026 16:44:00 -0400 ELOX O.02268824 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Eloxx+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932028.html si-local-file:///var/storage/secattach/20260814/26932028.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Eloxx+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932028.html Fri, 14 Aug 2026 16:44:00 -0400 ELOX O.02268824 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/PRNewswire/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/PRNewswire/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/PRNewswire/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/PRNewswire/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064 http://www.streetinsider.com/PRNewswire/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html <div class="xn-content"> <ul type="disc"><li><i>Completed underwritten public offering with gross proceeds of <money>$66.0 million</money> and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet</i></li><li><i>Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026</i></li><li><i><span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> granted orphan designation for exaluren in ADPKD</i></li><li><i>Cash and cash equivalents of <money>$62.0 million</money> as of <chron>June 30, 2026</chron>, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.arlton" idsrc="xmltag.org" >ARLINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ELOX" idsrc="xmltag.org" >Eloxx Pharmaceuticals, http://www.streetinsider.com/PRNewswire/Eloxx+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26908068.html Wed, 12 Aug 2026 06:00:00 -0400 A.06822034 A.17465503 A.35547030 A.41629270 A.50113834 A.60012004 ELOX O.00641452 O.00644142 O.01304637 O.02268824 O.20026344 O.22448340 O.28898064